全文获取类型
收费全文 | 2898篇 |
免费 | 208篇 |
国内免费 | 18篇 |
专业分类
耳鼻咽喉 | 16篇 |
儿科学 | 120篇 |
妇产科学 | 49篇 |
基础医学 | 345篇 |
口腔科学 | 72篇 |
临床医学 | 328篇 |
内科学 | 885篇 |
皮肤病学 | 28篇 |
神经病学 | 214篇 |
特种医学 | 58篇 |
外科学 | 395篇 |
综合类 | 28篇 |
一般理论 | 1篇 |
预防医学 | 239篇 |
眼科学 | 26篇 |
药学 | 143篇 |
中国医学 | 9篇 |
肿瘤学 | 168篇 |
出版年
2023年 | 21篇 |
2022年 | 46篇 |
2021年 | 82篇 |
2020年 | 48篇 |
2019年 | 89篇 |
2018年 | 89篇 |
2017年 | 60篇 |
2016年 | 62篇 |
2015年 | 69篇 |
2014年 | 104篇 |
2013年 | 150篇 |
2012年 | 202篇 |
2011年 | 235篇 |
2010年 | 129篇 |
2009年 | 111篇 |
2008年 | 181篇 |
2007年 | 209篇 |
2006年 | 167篇 |
2005年 | 183篇 |
2004年 | 158篇 |
2003年 | 136篇 |
2002年 | 135篇 |
2001年 | 29篇 |
2000年 | 24篇 |
1999年 | 30篇 |
1998年 | 33篇 |
1997年 | 38篇 |
1996年 | 23篇 |
1995年 | 11篇 |
1994年 | 10篇 |
1993年 | 15篇 |
1992年 | 16篇 |
1991年 | 10篇 |
1990年 | 14篇 |
1989年 | 10篇 |
1988年 | 7篇 |
1987年 | 12篇 |
1986年 | 14篇 |
1985年 | 9篇 |
1984年 | 10篇 |
1983年 | 11篇 |
1982年 | 12篇 |
1981年 | 9篇 |
1980年 | 14篇 |
1979年 | 10篇 |
1978年 | 9篇 |
1976年 | 7篇 |
1975年 | 8篇 |
1968年 | 6篇 |
1965年 | 5篇 |
排序方式: 共有3124条查询结果,搜索用时 15 毫秒
71.
Costanza Pellegrini Tobias Rheude Jonathan Michel Hector A. Alvarez-Covarrubias Sarah Wünsch N. Patrick Mayr Erion Xhepa Adnan Kastrati Heribert Schunkert Michael Joner Markus Kasel 《Journal of thoracic disease》2020,12(11):6769
BackgroundThis study compares two latest-generation self-expanding transcatheter heart valves (THV), the supra-annular ACURATE neo (Boston Scientific) and the intra-annular Centera THV (Edwards Lifesciences).MethodsIn this single center observational cohort trial 317 patients treated with the ACURATE neo and 78 patients treated with the Centera TVH were included. The main endpoints were device success and the early safety endpoint at 30 days.ResultsBesides higher incidence of diabetes mellitus and higher body mass index in patients treated with the ACURATE neo THV, there were no baseline differences between the groups. Device success was similar in both groups (neo: 91.8% vs. Centera: 93.6%; P=0.598), with numerically higher rates of moderate to severe paravalvular leakage in the ACURATE neo group (4.7% vs. 1.3%; P=0.214). At 30 days all-cause mortality rates were low in both groups (0.3% vs. 0%; P=0.620) and no difference occurred in the early safety at 30 days (19.3% vs. 16.7%; P=0.599). However, all-cause stroke rates were significantly higher in patients treated with the Centera THV (6.4 vs. 1.6%; P=0.015).ConclusionsThe ACURATE neo and the Centera THV show low mortality rates as well as comparable, favorable hemodynamics. The finding of higher stroke rates at 30 days with the repositionable Centera SE-THV needs further assessment. 相似文献
72.
Laura Villarreal‐Martínez Jaime García‐Chvez Berenice Snchez‐Jara Aida Mashenka Moreno‐Gonzlez Janet Soto‐Padilla Efraín Aquino‐Fernndez Rogelio Paredes‐Aguilera Karla Maldonado‐Silva Cecilia Rodríguez‐Castillejos Ana Itamar Gonzlez‐vila María Mora‐Torres Hector Manuel Tiznado‐García Natalia Elizabeth Padilla‐Durn Nuria Citlali Luna‐Silva Eric Israel Gutirrez‐Jurez Jorge Nemi‐Cueto Claudia Sofia Gmez‐Gonzlez Ricardo De Len‐Figueroa Adela Lpez‐Miranda Mirna Guadalupe Ríos‐Osuna Edna Liliana Tamez‐Gmez Elio Aarn Reyes‐Espinoza Irving Armando Domínguez‐Varela Gerardo Gonzlez‐Martínez Elias Adn Godoy‐Salinas 《Haemophilia》2020,26(2):290-297
73.
A CT‐based medina classification in coronary bifurcations: Does the lumen assessment provide sufficient information?
下载免费PDF全文
![点击此处可从《Catheterization and cardiovascular interventions》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Stella‐Lida Papadopoulou MD Chrysafios Girasis MD Frank J. Gijsen PhD Alexia Rossi MD Jade Ottema MD Alina G. van der Giessen PhD Johan C. Schuurbiers BSC Hector M. Garcia‐Garcia MD PhD Pim J. de Feyter MD PhD Jolanda J. Wentzel PhD 《Catheterization and cardiovascular interventions》2014,84(3):445-452
74.
Rajit K. Basu Yu Wang Hector R. Wong Lakhmir S. Chawla Derek S. Wheeler Stuart L. Goldstein 《Clinical journal of the American Society of Nephrology》2014,9(4):654-662
Background and objectives
Novel AKI biomarkers carry variable performance for prediction of AKI in patients with heterogeneous illness. Until utility is demonstrated in critically ill patients outside of the cardiopulmonary bypass population, AKI biomarkers are unlikely to gain widespread implementation. Operationalization of an AKI risk stratification methodology, termed renal angina, was recently reported to enhance prediction at the time of intensive care unit admission for persistent severe AKI. The renal angina index (RAI) was developed to provide the clinical context to direct AKI biomarker testing. This study tested the hypothesis that incorporation of AKI biomarkers in patients fulfilling renal angina improves the prediction of persistent severe AKI.Design, setting, participants, & measurements
In a multicenter study of 214 patients admitted to the pediatric intensive care unit with sepsis, the discrimination of plasma neutrophil gelatinase–associated lipocalin (NGAL), matrix metalloproteinase-8 (MMP-8), and neutrophil elastase-2 (Ela-2) were determined individually and in combination with the RAI for severe AKI. Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) were calculated.Results
Individual biomarkers demonstrated marginal discrimination for severe AKI (area under curve [AUC]: NGAL, 0.72; MMP-8, 0.68; Ela-2, 0.72), inferior to prediction by the clinical model of the RAI (AUC=0.80). Incorporation of each biomarker significantly added to the renal angina model AKI prediction (AUC=0.80, increased to 0.84–0.88; P<0.05 for each). The inclusion of each biomarker with the RAI demonstrated NRI (0.512, 0.428, and 0.545 for NGAL, MMP-8, and Ela-2, respectively; all P<0.03) and IDI (0.075 for Ela-2). The inclusion of both Ela-2 and NGAL with RAI demonstrated an NRI of 0.871 (P<0.001) and an IDI of 0.1 (P=0.01).Conclusions
This study shows that incorporation of AKI biomarkers into the RAI improves discrimination for severe AKI. The RAI optimizes the utility of AKI biomarkers in a heterogeneous, critically ill patient population. 相似文献75.
76.
Wang Y Marling SJ Zhu JG Severson KS DeLuca HF 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(22):8501-8504
The development of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis, has been studied in mice that were (i) vitamin D-deficient, (ii) minus the vitamin D receptor, (iii) minus a vitamin D 25-hydroxylase, and (iv) minus the vitamin D 25-hydroxyvitamin D-1α-hydroxylase. EAE development was markedly suppressed in mice lacking the vitamin D receptor and partially suppressed in vitamin D-insufficient mice. However, the absence of either of the two key hydroxylases (i.e., 25-hydroxylase and 1α-hydroxylase) neither inhibits nor enhances the development of EAE. These results indicate that vitamin D and the vitamin D receptor are required for the development of EAE. The results also suggest that 1,25-dihydroxyvitamin D(3) may not play a role in this autoimmune response. 相似文献
77.
Stewart JD Marchan R Lesjak MS Lambert J Hergenroeder R Ellis JK Lau CH Keun HC Schmitz G Schiller J Eibisch M Hedberg C Waldmann H Lausch E Tanner B Sehouli J Sagemueller J Staude H Steiner E Hengstler JG 《Proceedings of the National Academy of Sciences of the United States of America》2012,109(21):8155-8160
Metastasis from primary tumors remains a major problem for tumor therapy. In the search for markers of metastasis and more effective therapies, the tumor metabolome is relevant because of its importance to the malignant phenotype and metastatic capacity of tumor cells. Altered choline metabolism is a hallmark of cancer. More specifically, a decreased glycerophosphocholine (GPC) to phosphocholine (PC) ratio was reported in breast, ovarian, and prostate cancers. Improved strategies to exploit this altered choline metabolism are therefore required. However, the critical enzyme cleaving GPC to produce choline, the initial step in the pathway controlling the GPC/PC ratio, remained unknown. In the present work, we have identified the enzyme, here named EDI3 (endometrial differential 3). Purified recombinant EDI3 protein cleaves GPC to form glycerol-3-phosphate and choline. Silencing EDI3 in MCF-7 cells decreased this enzymatic activity, increased the intracellular GPC/PC ratio, and decreased downstream lipid metabolites. Downregulating EDI3 activity inhibited cell migration via disruption of the PKCα signaling pathway, with stable overexpression of EDI3 showing the opposite effect. EDI3 was originally identified in our screening study comparing mRNA levels in metastasizing and nonmetastasizing endometrial carcinomas. Both Kaplan-Meier and multivariate analyses revealed a negative association between high EDI3 expression and relapse-free survival time in both endometrial (P < 0.001) and ovarian (P = 0.029) cancers. Overall, we have identified EDI3, a key enzyme controlling GPC and choline metabolism. Because inhibition of EDI3 activity corrects the GPC/PC ratio and decreases the migration capacity of tumor cells, it represents a possible target for therapeutic intervention. 相似文献
78.
79.